Proton therapy for hematologic malignancies

Given the excellent outcomes, the treatment paradigm for Hodgkin lymphoma and other hematologic malignancies has shifted toward de-escalation. As long life expectancies are anticipated, patients must be spared the late treatment toxicities that can manifest decades later. Radiation dose and treatment volumes have been progressively deintensified. Recently, proton therapy has been highlighted as an ideal modality for such patients. The absence of exit dose allows decreased critical structure and total body radiation dose. The unique advantages of proton therapy align with the treatment goals for these patients and guarantee its future role in the treatment of hematologic malignancies.